BridgeBio Pharma Q4 Earnings Call Highlights

Chief Commercial Officer Matt Houghton said Attruby’s growth has been strongest in first-line patients and attributed momentum to the “exceptional data” for the therapy and the company’s field execution. He emphasized that the company has historically provided a quarterly “new patient start” figure, but said BridgeBio will stop reporting that metric going forward because competitors do not disclose comparable data and continued disclosure could create a competitive disadvantage.BridgeBio reiterated that Att ...